IN8BIO, INC. Finance Lease, Right-of-Use Asset, Amortization
IN8BIO, INC. (INAB) reported Finance Lease, Right-of-Use Asset, Amortization of $170.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- IN8BIO, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $62.00K, a 78.32% decline year-over-year.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $108.00K, a 55.00% decline year-over-year.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $119.00K, a 49.15% decline year-over-year.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $126.00K, a 44.74% decline year-over-year.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2025 was $771.00K, a 10.24% decline from fiscal 2024.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2024 was $859.00K, a 1.38% decline from fiscal 2023.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2023 was $871.00K, a 88.94% increase from fiscal 2022.
- IN8BIO, INC. finance lease, right-of-use asset, amortization for fiscal 2022 was $461.00K, a 14.15% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $170.00K 10-Q · filed 2026-08-06 | $289.00K derived: sum of 3 quarters · filed 2026-08-06 | $415.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $108.00K 10-Q · filed 2026-05-07 | $227.00K derived: sum of 2 quarters · filed 2026-05-07 | $353.00K derived: sum of 3 quarters · filed 2026-05-07 | $639.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $245.00K derived: sum of 2 quarters · filed 2026-03-12 | $531.00K derived: sum of 3 quarters · filed 2026-08-06 | $771.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $126.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $412.00K derived: sum of 2 quarters · filed 2026-08-06 | $652.00K 10-Q · filed 2025-11-06 | $886.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $286.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $526.00K 10-Q · filed 2026-08-06 | $760.00K derived: sum of 3 quarters · filed 2026-08-06 | $988.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $240.00K 10-Q · filed 2026-05-07 | $474.00K derived: sum of 2 quarters · filed 2026-05-07 | $702.00K derived: sum of 3 quarters · filed 2026-05-07 | $895.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $462.00K derived: sum of 2 quarters · filed 2026-03-12 | $655.00K derived: sum of 3 quarters · filed 2026-03-12 | $859.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $421.00K derived: sum of 2 quarters · filed 2025-11-06 | $625.00K 10-Q · filed 2025-11-06 | $840.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $397.00K 10-Q · filed 2025-08-07 | $612.00K derived: sum of 3 quarters · filed 2025-08-07 | $850.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $204.00K 10-Q · filed 2025-05-07 | $419.00K derived: sum of 2 quarters · filed 2025-05-07 | $657.00K derived: sum of 3 quarters · filed 2025-05-07 | $887.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $453.00K derived: sum of 2 quarters · filed 2025-03-13 | $683.00K derived: sum of 3 quarters · filed 2025-03-13 | $871.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $238.00K 10-Q · filed 2023-11-09 | $468.00K derived: sum of 2 quarters · filed 2023-11-09 | $656.00K 10-Q · filed 2024-11-12 | $776.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $230.00K 10-Q · filed 2023-08-10 | $418.00K 10-Q · filed 2024-08-08 | $538.00K derived: sum of 3 quarters · filed 2024-05-09 | $628.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $188.00K 10-Q · filed 2024-05-09 | $308.00K derived: sum of 2 quarters · filed 2024-05-09 | $398.00K derived: sum of 3 quarters · filed 2024-05-09 | $500.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $210.00K derived: sum of 2 quarters · filed 2024-03-14 | $312.00K derived: sum of 3 quarters · filed 2024-03-14 | $461.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $90.00K 10-Q · filed 2023-11-09 | $192.00K derived: sum of 2 quarters · filed 2023-11-09 | $341.00K 10-Q · filed 2023-11-09 | $486.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $102.00K 10-Q · filed 2023-08-10 | $251.00K 10-Q · filed 2023-08-10 | $396.00K derived: sum of 3 quarters · filed 2023-08-10 | $537.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $149.00K 10-Q · filed 2023-05-12 | $294.00K derived: sum of 2 quarters · filed 2023-05-12 | $435.00K derived: sum of 3 quarters · filed 2023-05-12 | $573.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $286.00K derived: sum of 2 quarters · filed 2023-03-30 | $424.00K derived: sum of 3 quarters · filed 2023-03-30 | $537.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | $141.00K 10-Q · filed 2022-11-10 | $279.00K derived: sum of 2 quarters · filed 2022-11-10 | $392.00K 10-Q · filed 2022-11-10 | $392.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $138.00K 10-Q · filed 2022-08-12 | $250.00K 10-Q · filed 2022-08-12 | $251.00K derived: sum of 3 quarters · filed 2022-08-12 | $251.00K derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $113.00K 10-Q · filed 2022-05-12 | $113.00K derived: sum of 2 quarters · filed 2022-05-12 | $113.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |